ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good?
|
|
- Silvia Austin
- 5 years ago
- Views:
Transcription
1 ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good? STEPHANIE M. OZALAS, PHARMD, BCPS, BCGP VA MARYLAND HEALTH CARE SYSTEM BALTIMORE, MD DISCLOSURES Off-label use of medications will be discussed during this presentation. The speaker served as a content expert for the ASCP geriatrics pharmacy review (GPR) course. 1
2 PHARMACIST OBJECTIVES 1. Given a patient case, analyze psychotropic regulatory compliance in long term care using the CMS State Operations Manual. 2. Compare and contrast the efficacy of at least 2 different antipsychotics for the treatment of behavioral and psychological symptoms of dementia. 3. Given a patient case, evaluate the appropriateness of antipsychotic prescription and recommend alternatives based on evidence-based literature. TECHNICIAN OBJECTIVES 1. Identify common dose ranges for antipsychotics when used to treat behavioral and psychological symptoms of dementia. 2. Relate antipsychotic adverse effects to their receptor affinities. OUTLINE Background Antipsychotic use in dementia Antipsychotic literature evaluation Alternatives to antipsychotics Treatment approach to behavioral and psychological symptoms of dementia (BPSD) Case breakout session Conclusion 2
3 BACKGROUND DEFINITION AND EPIDEMIOLOGY OF DEMENTIA EPIDEMIOLOGY Figure: International, A.s.D. World Alzheimer Report; DEMENTIA DEFINITION Neurocognitive disorder (per DSM-V) Diagnosis Minor Neurocognitive Disorder Major Neurocognitive Disorder *Not due to: delirium, other mental disorder Characteristics Moderate cognitive decline Does not interfere with ADLs Significant cognitive decline Interferes with ADLs American Psychiatric Association. Neurocognitive Disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 5 th ed
4 DIAGNOSIS TYPES OF DEMENTIA Alzheimer s disease (AD) Vascular Mixed Lewy Body Parkinson s Fronto- Temporal BPSD DEFINITION Hallucinations Repetitive Activities Delusions BPSD Wandering Paranoia Aggression 4
5 Dementia population will experience one or more BPSD Unpaid caregiver hours per year provided to those with dementia Quick Facts. Alzheimer s Association. Cincinnati, OH. Modified from: Walters SA. 1/2016. Which form of dementia is characterized by decreased attention, motor dysfunction, and well-formed hallucinations? ANTIPSYCHOTIC USE IN DEMENTIA RISK AND GUIDELINES FOR USE 5
6 ANTIPSYCHOTICS BLACK BOX WARNING WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death compared to placebo. Increased risk of death due to: o Stroke o Sudden cardiac death and heart failure o Infections NNH = 83 This BBW was placed on all atypical antipsychotics in 2005 and then was extended to include typical antipsychotics in 2008 Need to weigh risks versus benefits Improving Antipsychotic Appropriateness in Dementia Patients [Internet].: Iowa Geriatric Education Center Slide Credit: Walters SA. 1/2016. THE RISK REALIZED 5.5 Million People with AD 90% with BPSD 4.95 Million People with AD and BPSD Antipsychotic Treatment: NNH = 83 ~60,000 potential deaths/year due to antipsychotics Modified from: Walters SA. 1/2016. AMERICAN PSYCHIATRIC ASSOCIATION Assessment Assess type, frequency, severity, pattern, and timing of symptoms Assess potentially modifiable contributors Benefits and Risks Only use when symptoms are severe, dangerous and/or cause significant distress to patient Implement and review response to non-pharmacologic interventions Antipsychotics Use and Monitoring Initiate at low dose and titrate to effective dose If no clinically significant response in 4 weeks, discontinue Discuss dose titrations with patient s surrogate decision maker Avoid short-acting haloperidol for chronic use American Psychiatric Association. Am J Psychiatry 173:5:
7 AMERICAN GERIATRICS SOCIETY A systematic review of prospective studies including 6 single-agent and 7 comparison studies Small study populations and limited methodologies throughout the various studies Rates of delirium resolution in non-medication intervention studies were similar to that of the antipsychotic studies in this review This review does not support using antipsychotics for delirium in hospitalized elderly patients Flaherty JH, Gonzales JP, Dong B. J Am Geriatr Soc. 59 Suppl 2:S269-76, 2011 Nov. CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) REGULATIONS F757: Unnecessary Medications Any drug when used: In excessive dose For excessive duration Without adequate monitoring Without adequate indications for use In the presence of adverse consequences which indicate the dose should be reduced or discontinued Any combinations of the above Centers for Medicare and Medicaid Services. State Operations Manual Appendix PP CMS REGULATIONS (cont.) F758: Psychotropic Drugs Definition: any drug that affects brain activities associated with mental processes and behavior Antipsychotic Antidepressant Antianxiety Hypnotic Others: anticonvulsants, antihistamines, anticholinergics, antiemetics, muscle relaxants, mood stabilizers, NMDA receptor modulators Centers for Medicare and Medicaid Services. State Operations Manual Appendix PP
8 CMS REGULATIONS (cont.) F758: Psychotropic Drugs [Gradual Dose Reduction (GDR)] Most Psychotropics (including antipsychotics) Twice in first year in two separate quarters Annually Sedative/Hypnotics/Benzodiazepines Quarterly Clinical Contraindication: Resident s symptoms returned or worsened after the most recent GDR attempt AND Attempted further dose reduction would likely impair resident s function or cause psychiatric instability Centers for Medicare and Medicaid Services. State Operations Manual Appendix PP CMS REGULATIONS UPDATES F758: Psychotropic Drugs [Duration] PRN Psychotropic Orders Specific condition diagnosed and documented in the medical record 14 day limit unless rationale in medical record PRN Antipsychotic Orders 14 day limit (no exceptions) Renewal requires attending or prescriber evaluation Centers for Medicare and Medicaid Services. State Operations Manual Appendix PP What are the most common causes of death related to antipsychotic use in elderly individuals with dementia? 8
9 ANTIPSYCHOTIC LITERATURE EVALUATION FIRST AND SECOND GENERATION ANTIPSYCHOTICS CATIE-AD METHODS Design Double-blind, placebo-controlled Intervention: Olanzapine v. Quetiapine v. Risperidone v. Placebo Population Outcomes Inclusion: Ambulatory Alzheimer disease, MMSE 5-26, BPSD symptoms for at least 4 weeks Exclusion: Psychotic disorder, delirium, other dementia, substance abuse; new acetylcholinesterase inhibitor or antidepressant medication Primary: Time until discontinuation of treatment for any reason Secondary: Attainment of minimal or greater improvement in CGIC scale at 12 weeks Safety: Weight, prolactin, glucose, cholesterol, triglycerides at weeks 12, 24, 36 Schneider LS, Tariot PN, Dagerman KS, et al. NEJM 2006;355(15): CATIE-AD CHARACTERISTICS Characteristic Olanzapine (n=99) Quetiapine (n=94) Risperidone (n=84) Placebo (n=139) MMSE (n) Total NPI, total (n) Delusions (%) Hallucinations (%) Agitation (%) Medications Antidepressant (%) Atypical Antipsychotic (%) Cholinesterase Inhibitor(%) Schneider LS, Tariot PN, Dagerman KS, et al. NEJM 2006;355(15):
10 CATIE-AD OUTCOMES: EFFICACY Schneider LS, Tariot PN, Dagerman KS, et al. NEJM 2006;355(15): CATIE-AD OUTCOMES: SAFETY Schneider LS, Tariot PN, Dagerman KS, et al. NEJM 2006;355(15): CONCLUSIONS No large clinical benefit of treatment for BPSD with atypical antipsychotic medications compared to placebo Discontinuation of antipsychotic for any reason was similar between groups Discontinuation due to lack of efficacy: Placebo Quetiapine > Risperidone and Olanzapine Discontinuation due to adverse effects: Olanzapine > Quetiapine and Risperidone > Placebo Schneider LS, Tariot PN, Dagerman KS, et al. NEJM 2006;355(15):
11 ANTIPSYCHOTICS Typical Antipsychotics (haloperidol, thioridazine, thiothixene, chlorpromazine, trifluoperazine) Haloperidol: Some efficacy for aggression (but not agitation) with drop-out rates due to adverse effects. Thioridazine: Improvement in anxiety, but clinical significance unclear Recommendation: No clear evidence for the effectiveness of any typical antipsychotic in the treatment of dementiarelated symptoms. Haloperidol ( mg/dose) may show some improvement in aggression. Atypical Antipsychotics (clozapine, olanzapine, risperidone, quetiapine, ziprasidone, and aripiprazole) Risperidone: Both 1mg and 2mg doses showed equiefficacious improvements in BPSD, but the 2 mg dose resulted in significantly higher adverse events. Olanzapine: Only low-dose (5mg/day) showed improvements in overall agitation/aggression, hallucinations and delusions. Quetiapine: No significant improvements on BPSD. Aripiprazole: Mixed results with unclear clinical significance. Recommendation: Risperidone (1mg/dose) and olanzapine (5-10mg/dose) are modestly effective at improving these dementia-related symptoms. Sink K, et al. JAMA: 2005;293(5): ; Gareri P, et al. J Clin Psychopharmacol 2014;34: Modified from: Walters SA. 1/2016. EFFICACY SUMMARY: ATYPICALS Aripiprazole Olanzapine Quetiapine Risperidone Dementia Overall Dementia Psychosis Dementia Agitation /- +/ /- ++ Improving Antipsychotic Appropriateness in Dementia Patients [Internet].: Iowa Geriatric Education Center Drug ANTIPSYCHOTIC DOSING GUIDE Starting Dose (mg/day) Max Maintenance Dose (mg/day) Special Dosage Forms Aripiprazole ODT, L, IM Haloperidol C, L, IM Olanzapine ODT, L, IM Quetiapine SR Risperidone ODT, L Abbreviations: C = oral concentrate, L = liquid, IM = short-acting intramuscular, ODT = oral disintegrating tablet, SR = sustained release Improving Antipsychotic Appropriateness in Dementia Patients [Internet].: Iowa Geriatric Education Center
12 RELATIVE ADVERSE EFFECTS Receptor Haloperidol Aripiprazole Olanzapine Quetiapine Risperidone D 2 Dopamine EPS 5HT 2A Serotonin Anti-EPS 5HT 2C Serotonin Weight Gain α 1 Adrenergic Sedation, Hypotension H 1 Histamine Sedation, Weight Gain M 1 Muscarinic Delirium, Anticholinergic (partial agonist) Richelson E. J Clin Psychiatry 2010;71(9): Receptor Haloperidol Aripiprazole Olanzapine Quetiapine Risperidone Hypertriglyerceridemia QT Prolongation +/-? +/- +/- +/- Urinary Incontinence RELATIVE ADVERSE EFFECTS (cont.) Improving Antipsychotic Appropriateness in Dementia Patients [Internet].: Iowa Geriatric Education Center PIMAVANSERIN 5-HT 2A inverse agonist and antagonist, low affinity for 5-HT 2C receptors No dopaminergic activity FDA approved for psychosis in Parkinson s disease (PD) Dosage: 34mg by mouth Daily Strong CYP3A4 inhibitors: 17mg by mouth Daily Adverse Effects: Orthostatic hypotension, CNS depression, Peripheral edema, Nausea, Constipation, QTc prolongation (rare) 12
13 PIMAVANSERIN CLINICAL TRIALS PARKINSON S PSYCHOSIS 1 Methods: Phase 3 placebocontrolled blinded RCT Inclusion Criteria: Age >40, diagnosed PD 1 year, severe psychotic symptoms weekly, MMSE 21 Primary Outcome: Change in SAPS-PD score from baseline to Day 43 37% v. 14% SAPS-PD improvement (p<0.001) No significant effects on movements, orthostasis ALZHEIMER S PSYCHOSIS 2 Methods: Phase 2 placebocontrolled double-blinded RCT Inclusion Criteria: Age >50, diagnosed AD and psychosis, severe psychotic symptoms weekly x2 weeks, NPI 6, NH placement 4 weeks without discharge Primary Outcome: Change in NPI- NH psychotic score from baseline to Day v NPI-NH psychosis score (p=0.045) No difference in total NPI scores 1. Cummings J, Isaacson S, Mills R, et al. Lancet 2014;383: Ballard C, Banister C, Khan Z, et al. 2018;17: Pharmacists: In the CATIE-AD trial, which antipsychotic was not statistically significantly different from placebo for the outcome of discontinuation due to lack of efficacy? Technicians: Which antipsychotic studied for dementia with BPSD is associated with the least extrapyramidal symptoms? ALTERNATIVE TO ANTIPSYCHOTICS NON-PHARMACOLOGIC AND PHARMACOLOGIC OPTIONS 13
14 KNOW YOUR ABCS OF DEMENTIA A B C Activator What happened just before B? Behavior What was the patient doing? Who was present? Where was this happening? When was this happening? Consequence What happened just after B? Did this make the behavior better or worse? Star-VA Program: The ABCs of Dementia. Presentation by French JL, Obrien S. REVERSIBLE CAUSES OF BPSD Unmet physical needs Pain Infection Dehydration/nutrition Sleep disturbances Constipation Unmet psychological needs Loneliness Boredom Environmental causes Noise Lighting Caregiver approaches Lack of cues/prompts Psychiatric causes Depression Anxiety Delirium Improving Antipsychotic Appropriateness in Dementia Patients [Internet].: Iowa Geriatric Education Center NON-PHARMACOLOGIC ALTERNATIVES Cognitive/Emotion-oriented therapies Reminiscence/ Simulated presence therapy Validation therapy Sensory stimulation Massage and touch, Music therapy, Snoezelen therapy Behavior management Patient-specific behavioral evaluation Animal-assisted therapy Exercise O Neil M et al. Department of Veteran Affairs; Modified from: Walters SA. 1/
15 NON-PHARMACOLOGIC EXAMPLES Cues, prompts, reminders Simplified daily routine Speak in clear, simple phrases Do not challenge Personalized or group activities Eliminate distractors Reduce stress Reduce clutter Reduce sources for threats Adapt environment to reduce exit-seeking Individualized music Reassure Improving Antipsychotic Appropriateness in Dementia Patients [Internet].: Iowa Geriatric Education Center ALTERNATIVES NON-PHARMACOLOGIC Sensory stimulation Behavior management techniques Animal-assisted therapy Exercise PHARMACOLOGIC Antidepressants Cholinesterase inhibitors Mood stabilizers NDMA-receptor antagonists Memantine Dextromethorphan/ Quinidine ANTIDEPRESSANTS Antidepressants (Selective Serotonin Reuptake Inhibitors [SSRIs]) (fluoxetine, trazodone, citalopram, and sertraline) Sertraline: No effect on neuropsychiatric symptoms, but did show an improvement in depression in dementia patients. 1 Citalopram: - A significant improvement in agitation and mood lability were seen compared to placebo in a 17 day study. 1 - Further studies supported these findings of clinically significant improvement of agitation/aggression and caregiver distress with citalopram. 2,3 - The CitAD trial further showed efficacy for agitation in AD; however, target dose was citalopram 30mg daily, which is associated with a higher risk of QT prolongation. 3 Recommendation: Although they are well-tolerated, antidepressants do not appear to be very effective overall in treating neuropsychiatric symptoms. Citalopram 20mg daily may be an option for agitation symptoms. 1. Sink K, et al. JAMA: 2005;293(5): ; 2. Pollock BG et al. Am J Geriatr Psychiatry. 2007;15(11): ; 3. Porsteinsson A et al. JAMA. 2014;311(7): Slide Credit: Walters SA. 1/
16 CHOLINESTERASE INHIBITORS (AChEIs) Cholinesterase Inhibitors (AChEIs) (rivastigmine, donepezil, and galantamine) Donepezil: Conflicting results from 4 RCTs. One showed improvements in agitation/aggression. Another showed improvement in depression, anxiety, and apathy. 1 Continuation of AChEIs in moderate-severe dementia may hasten cognitive and functional decline. 2 Initiation of AChEIs may reduce BPSD, but clinical significance unknown. 3 Galantamine: Only the 16mg/dose showed a small but significant improvement in the Neuropsychiatric Inventory (NPI) scale compared to placebo. 1 Recommendation: Donepezil and galantamine may provide some small improvement that may not prove clinically significant Sink K, et al. JAMA: 2005;293(5): Howard R et al. N J Engl Med 2014;366(10): Campbell N, et al. Clin Inter Aging 2008;3(4): Slide Credit: Walters SA. 1/2016. MOOD STABILIZERS Mood Stabilizers (valproate and carbamazepine) Carbamazepine: One 6 week study showed an improvement in agitation compared to placebo; although, another study showed no improvements in these target symptoms. Valproate: No significant improvement and increased risk of ADRs. Recommendation: The use of valproate is not recommended, due to lack of efficacy and significantly higher ADRs. There is currently not enough data to support the use of carbamazepine. Sink K, et al. JAMA: 2005;293(5): Slide Credit: Walters SA. 1/2016. NMDA RECEPTOR ANTAGONISTS Memantine Memantine: Mixed results from 2 RCTs. 1 One showed no difference in symptoms. The other showed a significant difference compared to placebo due to the placebo-group s declining health and increased symptoms. Recommendation: There does not appear to be a direct role for memantine in the management of BPSD. Dextromethorphan/ Quinidine (DM/Q) (Nuedexta ) DM/Q: One phase 2, 10 week RCT for treatment of agitation in Alzheimer s disease. A statistically significant improvement was seen in agitation/aggression per the NPI. 2 Recommendation: Dextromethorphan/quinidine may be considered as a second or third line agent specifically for significant agitation in those with Alzheimer s disease. Drugdrug interactions with CYP2D6 should be evaluated. 1. Sink K, et al. JAMA 2005;293(5): Cummings JL et al. JAMA 2015;314(12): Slide Credit: Walters SA. 1/
17 BPSD TREATMENT ALGORITHM BPSD Yes Nonpharmacologic No SSRI AChEI with or without memantine Consider DM/Q Atypical antipsychotic^ SSRI Carbamazepine DM/Q Evaluate for reversible causes Depression or anxiety? Consult specialist *If intervention is effective, monitorfor reoccurrence and adverse effects ^ Consider pimavanserin for patientswith PD andpsychosis. Modified from: Sink K, et al. JAMA: 2005;293(5): What non-pharmacologic strategies have been proven effective to decrease BPSD? CASE BREAKOUT SESSION 17
18 CASE DISCUSSION A B C Activator What happened just before B? Behavior What was the patient doing? Who was present? Where was this happening? When was this happening? Consequence What happened just after B? Did this make the behavior better or worse? Star-VA Program: The ABCs of Dementia. Presentation by French JL, Obrien S. Which classes of non-antipsychotic psychotropics have at least a moderate quality of evidence to support their use for BPSD? Hopefully, not these drugs! CONCLUSION BPSD is a common symptom associated with dementia. Use of antipsychotics for the treatment of BPSD is associated with an increased risk for death. Antipsychotic use in long term care facilities is highly regulated by CMS and GDR documentation is required. Non-pharmacologic interventions should always be attempted first. Evidenced based medicine indicates some benefits of aripiprazole, olanzapine, and risperidone for BPSD. Some SSRIs and AChEIs may also be helpful in managing BPSDrelated syndromes. 18
19 MORE INFORMATION: Iowa Geriatric Education Center: IA-ADAPT Toolkit: 19
Antipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More informationPsychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD
Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences
More informationMEDICATIONS IN MANAGING DIFFICULT BEHAVIORS
MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS A REALITY CHECK reality check Noun informal an occasion on which one is reminded of the state of things in the real world. ROBERT LACOSTE, MD MEDICAL DIRECTOR,
More informationNeurocognitive Disorders Research to Emerging Therapies
Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia
More informationDebra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017
Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic
More information11/11/2016. Disclosures. Natural history of BPSD. Objectives. Assessment of BPSD. Behavioral Management of Persons with Alzheimer s Disease
Disclosures Behavioral Management of Persons with Alzheimer s Disease Wisconsin Association of Medical Directors November 17, 2016 Art Walaszek, M.D. Professor of Psychiatry UW School of Medicine & Public
More informationDisclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA
Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer
More informationUSING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE?
USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE? Mugdha Thakur, MD Associate Professor of Psychiatry and Behavioral Sciences Duke University
More informationPresented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD
Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD Define BPSD and review the spectrum of associated symptoms Review pharmacologic and non-pharmacologic treatments for BPSD Evaluate
More informationClinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease
Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Professor Clive Ballard Dr Byron Creese University of Exeter, UK Guardian guide for 2018: Top
More informationPsychosis and Agitation in Dementia
Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University
More informationPsychotropic Medication Use in Dementia
Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationPharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018
Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018 Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology UNTHSC Center for Geriatrics 855 Montgomery Street, PCC 4, Ft.
More informationPharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital
Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital with thanks to Jonathan Cavan for his input Aims Define BPSD and common symptoms
More informationBEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA
BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA Unmet needs What might be your behavioural response to this experience? Content Definition What are BPSD? Prevalence How common are they? Aetiological
More informationManagement of Agitation in Dementia. Kimberly Triplett Ferguson, MS4
Management of Agitation in Dementia Kimberly Triplett Ferguson, MS4 Objectives 1. Review recommended evaluation of agitated patients with dementia. 2. Discuss evidence concerning nonpharmacologic management.
More informationPsychotropic Strategies Handout Package
Psychotropic Strategies Handout Package Psychotropic Strategies Learning Objectives Utilize all clinical information available Assess the patient s overall condition this is essential Basic Principles
More informationAntipsychotics for Dementia Under Control or Over-Prescribed?
Antipsychotics for Dementia Under Control or Over-Prescribed? Nathaniel Hedrick, PharmD ProCare HospiceCare, Manager of Clinical Services Learning Objectives Summarize the disease progression and most
More informationPsychotropic Medication. Including Role of Gradual Dose Reductions
Psychotropic Medication Including Role of Gradual Dose Reductions What are they? The phrase psychotropic drugs is a technical term for psychiatric medicines that alter chemical levels in the brain which
More informationNuplazid. (pimavanserin) New Product Slideshow
Nuplazid (pimavanserin) New Product Slideshow Introduction Brand name: Nuplazid Generic name: Pimavanserin Pharmacological class: Atypical antipsychotic Strength and Formulation: 17mg; tablets Manufacturer:
More informationPharmacotherapy of Dementia Behaviors
This Clinical Resource gives subscribers additional insight related to the Recommendations published in June 2017 ~ Resource #330601 Pharmacotherapy of Dementia Behaviors (Also see our chart specific to
More informationManagement of the Acutely Agitated Long Term Care Patient
Management of the Acutely Agitated Long Term Care Patient 80 60 Graying of the Population US Population Over Age 65 Millions of Persons 40 20 0 1900 1920 1940 1960 1980 1990 2010 2030 Year Defining Dementia
More informationPharmacological Treatment of Aggression in the Elderly
Pharmacological Treatment of Aggression in the Elderly Howard Fenn, MD Adjunct Clinical Associate Professor Department of Psychiatry and Behavioral Sciences Stanford University Self-Assessment Question
More informationOptimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches
Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Andrea Iaboni, MD, DPhil, FRCPC Toronto Rehab Institute, UHN Learning objectives Recognize
More informationAny interventions, where RCTs in PD are not available, are not included in the tables.
Tables Interventions where new studies have been published are indicated in bold italics. Changes in conclusions are indicated in italics and are highlighted in yellow. Any interventions, where RCTs in
More information9/11/2012. Clare I. Hays, MD, CMD
Clare I. Hays, MD, CMD Review regulatory background for current CMS emphasis on antipsychotics Understand the risks and (limited) benefits of antipsychotic medications Review non-pharmacologic management
More informationBEHAVIORAL PROBLEMS IN DEMENTIA
BEHAVIORAL PROBLEMS IN DEMENTIA CLINICAL FEATURES Particularly as dementia progresses, psychiatric symptoms may develop that resemble discrete mental disorders such as depression or mania The course and
More informationMANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA
MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA Dr. Dallas Seitz MD PhD FRCPC Associate Professor and Division Chair, Division of Geriatric Psychiatry Department of Psychiatry, Queen s University President,
More informationTreatment of behavioral and psychological symptoms of dementia: a systematic review
Psychiatr. Pol. 2016; 50(4): 679 715 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: http://dx.doi.org/10.12740/pp/64477 Treatment of behavioral and psychological symptoms
More informationAssessment and management of behavioral and psychological symptoms of dementia
Assessment and management of behavioral and psychological symptoms of dementia Helen C Kales, 1 2 3 Laura N Gitlin, 4 5 6 Constantine G Lyketsos 7 1 Section of Geriatric Psychiatry, Department of Psychiatry,
More informationCognitive enhancers PINCH ME. Anticholinergic burden BPSD. Agitation, Aggression and antipsychotics
Cognitive enhancers PINCH ME Anticholinergic burden BPSD Agitation, Aggression and antipsychotics 2 types Cholinesterase inhibitors licensed for mild to moderate AD Donepezil Galantamine Rivastigmine also
More informationBehavioral and Psychological Symptoms of dementia (BPSD)
Behavioral and Psychological Symptoms of dementia (BPSD) Chris Collins - Old Age Psychiatrist, Christchurch chris.collins@cdhb.health.nz Approaching BPSD: the right mindset Assessment Non-drug management
More informationBehavioral Issues in Dementia. March 27, 2014 Dylan Wint, M.D.
Behavioral Issues in Dementia March 27, 2014 Dylan Wint, M.D. OVERVIEW Key points Depression Definitions and detection Treatment Psychosis Definitions and detection Treatment Agitation SOME KEY POINTS
More informationONCE-DAILY DOSING WITH NUPLAZID
YOUR GUIDE TO ONCE-DAILY DOSING WITH NUPLAZID NUPLAZID (pimavanserin) is the first and only FDAapproved treatment for hallucinations and delusions associated with Parkinson s disease psychosis 1 Indication
More informationEvaluation and Management of Agitation and Aggression in Dementia Joseph W. Shega, MD National Medical Director
Evaluation and Management of Agitation and Aggression in Dementia Joseph W. Shega, MD National Medical Director Objectives Differentiate between delirium, terminal restlessness, and dementia related agitation
More informationGuidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care
Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia
More informationAntipsychotics. Something Old, Something New, Something Used to Treat the Blues
Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer
More informationImproving Antipsychotic Appropriateness in Dementia Patients. Disclosures
Improving Antipsychotic Appropriateness in Dementia Patients Ryan Carnahan, Pharm.D., M.S., BCPP Assistant Professor (Clinical) The University of Iowa College of Public Health Department of Epidemiology
More informationOrganization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit
Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit Problem: For dementia patients, antipsychotic medications are prescribed
More informationObjectives. Antipsychotics 7/25/2016. LeadingAge Florida 53rd Annual Convention & Exposition
Reducing the Use of Antipsychotics in Long Term Care Communities Alan W. Obringer RPh, CPh, CGP Executive Director Senior Care Pharmacy Objectives Recognize the clinical evidence for the need to change
More informationDEMENTIA AND MEDICATION
DEMENTIA AND MEDICATION Dr. Siobhan Ni Bhriain, MRCP, MRCPsych. Clinical Director, Tallaght and SJH MHS, Consultant Old Age Psychiatrist, Chair, DSIDC Steering Committee. SUMMARY OF TODAY S TALK Dementia-definition,
More informationCorporate Presentation August 6, 2015
Corporate Presentation August 6, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events
More informationImproving Antipsychotic Appropriateness in Dementia Patients. Disclosures. The Challenge 4/21/2014
Improving Antipsychotic Appropriateness in Dementia Patients Ryan Carnahan, Pharm.D., M.S., BCPP Associate Professor (Clinical) The University of Iowa College of Public Health Department of Epidemiology
More informationGradual Dose Reduction and Medication Tapering: A Clinical Perspective
Gradual Dose Reduction and Medication Tapering: A Clinical Perspective Recent changes in the State Operations Manual put new emphasis on attempts to gradually reduce the dose of certain medications namely
More informationAntipsychotic Use in the Elderly
Antipsychotic Use in the Elderly Presented by: Fatima M. Ali, PharmD, RPh, BCPS Clinical Consultant Pharmacist MediSystem Pharmacy, Kingston Originally Prepared by: Nicole Tisi BScPhm, RPh ACPR Disclosure
More informationNovember 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by
November 16-18, 2017 Hotel Monteleone New Orleans, LA Provided by Major Neurocognitive Disorder: The Beginning and the End. Making the Diagnosis and Addressing Distressing Behavior W. Vaughn McCall, MD,
More informationFrom Neurodevelopment to Neurodegeneration: Behavioral Issues
From Neurodevelopment to Neurodegeneration: Behavioral Issues Amer M. Burhan, MBChB, FRCPC Associate Professor and Chair Geriatric Psychiatry at Western U Objectives Discuss factors that contribute to
More informationDementia: Managing Difficult Behaviors. No conflicts of interest. Off-label medication use will be discussed during this talk.
Dementia: Managing Difficult Behaviors No conflicts of interest. Off-label medication use will be discussed during this talk. 1 Types of Neurocognitive Disorder Alzheimer s Disease Vascular Frontotemporal
More informationLewy Body Disease. Dementia Education for the First Responder July 27, 2017
Lewy Body Disease Dementia Education for the First Responder July 27, 2017 Dylan Wint, M.D. NV Energy Chair for Brain Health Education Cleveland Clinic Lou Ruvo Center for Brain Health OUTLINE Lewy body
More informationMedications and Non-Pharma Approaches to Treatment. David J. Irwin, MD Penn Frontotemporal Degeneration Center
Medications and Non-Pharma Approaches to Treatment David J. Irwin, MD Penn Frontotemporal Degeneration Center Outline Non-Pharmacological Treatment Strategies Behavior Language Motor Supportive Care Check-points
More informationAntidepressants. Dr Malek Zihlif
Antidepressants The optimal use of antidepressant required a clear understanding of their mechanism of action, pharmacokinetics, potential drug interaction and the deferential diagnosis of psychiatric
More informationAppendix N: Research recommendations
Appendix N: recommendations N.1 First-line treatment of motor symptoms recommendation 1 Interventions What is the effectiveness of initial levodopa monotherapy versus initial levodopa-dopamine agonist
More informationFriend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines
Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines Program Learning Objectives At the conclusion of the activity, participants should be able to: Have a basic understanding
More informationUse of Psychotropic Medications in Older Adults with Dementia!
Use of Psychotropic Medications in Older Adults with Dementia! Deepa Pattani, PharmD, RPh Owner: PrevInteract Health Deepa.Pattani@PrevInteract.com 972-372-9775 About Me Deepa Pattani, PharmD, RPh with
More informationMedications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation
Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
More informationNeuroPharmac Journal ISSN: Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M.
ISSNISSN ISSN: 2456-3927 NeuroPharmac Journal Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M. Alshahrani www. neuropharmac.com Jan-April 2018, Volume 3, Issue
More informationDRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future
DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY
More informationCOMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK
COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK Robert L Alesiani, PharmD, CGP Chief Pharmacotherapy Officer CareKinesis, Inc. (a Tabula Rasa Healthcare Company) 2 3 4 5 Pharmacogenomics
More informationCoordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis
Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis Jeff Gelblum, MD Senior Attending Neurologist Mt. Sinai Medical Center Miami,
More informationNew Medications in Early Psychosis
New Medications in Early Psychosis Jean Starling Department of Psychological Medicine, the Children s Hospital at Westmead Department of Psychological Medicine and Department of Paediatrics and Child Health,
More informationDementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE
Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE Objectives At the conclusion of the session, participants will be
More informationAddressing Difficult Behaviors in Dementia
Addressing Difficult Behaviors in Dementia GEORGE SCHOEPHOERSTER, MD GERIATRICIAN GENEVIVE/CENTRACARE CLINIC Objectives By the end of the session, you will be able to: 1) Explain the role of pain management
More informationDrugs used to relieve behavioural and psychological symptoms in dementia
alzheimers.org.uk Drugs used to relieve behavioural and psychological symptoms in dementia People with dementia may develop behavioural and psychological symptoms including restlessness, aggression, delusions,
More informationThe place for treatments of associated neuropsychiatric and other symptoms
The place for treatments of associated neuropsychiatric and other symptoms Luca Pani dg@aifa.gov.it London, 25 th November 2014 Workshop on Alzheimer s Disease European Medicines Agency London, UK Public
More informationManagement of Behavioral Problems in Dementia
Management of Behavioral Problems in Dementia Ghulam M. Surti, MD Clinical Assistant Professor Department of Psychiatry and Human Behavior Warren Alpert Medical School of Brown University Definition of
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationPiecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder
Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder Hannah Sauer, PharmD PGY1 Pediatric Pharmacy Resident Mayo Clinic 2015 MFMER slide-1 Objectives
More informationCommunity Pharmacy Dementia Audit
Community Pharmacy Dementia Audit Introduction To comply with the NHS contractual requirements associated with the Clinical Governance Essential Service, pharmacy contractors must perform an annual practice
More informationUp to 90% of people with dementia experience
Focus on CME at the University of Calgary Getting Aggressive with Dementia Adrienne Cohen, MD, BSc, FRCPC Presented at Behaviour Problems in the Elderly, video-audio conference, 2003 Up to 90% of people
More informationMedications for treating people with dementia: summary of evidence on cost-effectiveness
Medications for treating people with dementia: summary of evidence on cost-effectiveness Martin Knapp, A-La Park and Alistair Burns PSSRU, London School of Economics and Political Science v4 23 July 2017
More informationAntipsychotics Detect, Select, Effect (P.I.E.C.E.S. 6 th Ed)
Antipsychotics Detect, Select, Effect (P.I.E.C.E.S. 6 th Ed) CLeAR Webinar February 14, 2014 Paula Diaz (Pharm) Carol Ward MD Carol Ward Tertiary Mental Health IHA Hillside Centre (Acute Tertiary Mental
More informationPSYCHOSIS: CHALLENGING ISSUES IN PARKINSON S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS
PSYCHOSIS: CHALLENGING ISSUES IN PARKINSON S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS Objectives Identify neurobiological substrates associated with Parkinson s disease psychosis Describe the differences
More informationMORTALITY ASSOCIATED WITH USE OF ANTIPSYCHOTICS IN DEMENTIA: REVIEWING THE EVIDENCE
MORTALITY ASSOCIATED WITH USE OF ANTIPSYCHOTICS IN DEMENTIA: REVIEWING THE EVIDENCE KRISTA L. LANCTÔT, PHD PROFESSOR OF PSYCHIATRY AND PHARMACOLOGY, UNIVERSITY OF TORONTO; SENIOR SCIENTIST, HURVITZ BRAIN
More informationRecognition and Management of Behavioral Disturbances in Dementia
Recognition and Management of Behavioral Disturbances in Dementia Danielle Hansen, DO, MS (Med Ed), MHSA INTRODUCTION 80% 90% of patients with dementia develop at least one behavioral disturbances or psychotic
More informationRational Medication Use in Dementia
Rational Medication Use in Dementia Stephen Thielke sthielke@u.washington.edu (206) 764 2815 I have no conflicts of interest to report. I am an employee of the federal government. The opinions in this
More informationNew England QIN-QIO Reducing Unnecessary Antipsychotic Medications Affinity Group Call Thursday, January 19 th 3-4:00 pm. Presenters.
New England QIN-QIO Reducing Unnecessary Antipsychotic Medications Affinity Group Call Thursday, January 19 th 3-4:00 pm Call-In Information: 1-888-895-6448 Code: 7362894 Log-In Information: https://qualidigm.adobeconnect.com/affinity/
More informationDiagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
More informationSchizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM
Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM NURS 203 GENERAL PHARMACOLOGY DANITA NARCISO PHARM D Learning Objectives Understand the result of dopamine binding to D2 receptors
More informationObjectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia
Objectives Identify positive and negative symptoms used for diagnosis of schizophrenia Mohamed Sallout, Pharm D. Pharmacist Resident St. Luke s Magic Valley Regional Medical Center List medications used
More informationDiagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical
Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical antipsychotics 1 Abstract Acute agitation and aggression
More informationMedication alternatives for behavioural disturbance
Neurology 13 Medication alternatives for behavioural disturbance Many patients with dementia will in the later stages develop distressing behavioural symptoms. Antipsychotics are commonly used to treat
More informationParkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations
Parkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations Pari Deshmukh MD Triple board-certified psychiatrist (Boards of psychiatry, addiction medicine, integrative
More informationRestrained use of antipsychotic medications:
Balanced information for better care Restrained use of antipsychotic medications: Rational management of irrationality These drugs are commonly prescribed in conditions for which there is little evidence
More informationPrimary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia
Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia This prescribing guideline provides the necessary information and guidance to support clinicians in the
More informationNuplazid. Nuplazid (pimavanserin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.03 Subject: Nuplazid Page: 1 of 4 Last Review Date: June 22, 2018 Nuplazid Description Nuplazid (pimavanserin)
More informationSlide 1. Slide 2. Slide 3. Risperidone Binding Profile. Risperidone Prescribing Facts. Risperidone Prescribing Facts
Slide 1 Risperidone Binding Profile (high affinity for D2 receptors) a 1 antagonist a 2 antagonist Slide 2 Risperidone Prescribing Facts 2 8 mg/day for acute psychosis and bipolar disorder 0.5-2 mg /day
More informationAntipsychotic Medications in the Treatment of Dementia with Behavior Disturbance
Antipsychotic Medications in the Treatment of Dementia with Behavior Disturbance American Association for Geriatric Psychiatry Los Angeles, CA March 2013 Maureen C. Nash, MD, MS, FAPA Medical Director,
More informationAlzheimer s Disease. Pathophysiology: Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior,
2 Alzheimer s Disease Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior, and functional status with no known cause or cure. Patients eventually lose cognitive, analytical,
More informationThe Basics of Psychoactive/Psychotropic Medications Tina Sanchez, RN, SMQT New Mexico Department of Health Division of Health Improvement State
The Basics of Psychoactive/Psychotropic Medications Tina Sanchez, RN, SMQT New Mexico Department of Health Division of Health Improvement State RAI/MDS Coordinator Objectives Upon completion of this training,
More informationDementia and Fall Geriatric Interprofessional Training. Wael Hamade, MD, FAAFP
Dementia and Fall Geriatric Interprofessional Training Wael Hamade, MD, FAAFP Prevalence of Dementia Age range 65-74 5% % affected 75-84 15-25% 85 and older 36-50% 5.4 Million American have AD Dementia
More informationTHIOTHIXENE. THERAPEUTICS Brands Navane see index for additional brand names. Generic? Yes
THIOTHIXENE THERAPEUTICS Brands Navane see index for additional brand names Generic? Yes Class Conventional antipsychotic (neuroleptic, thioxanthene, dopamine 2 antagonist) Commonly Prescribed for (bold
More informationA Basic Approach to Mood and Anxiety Disorders in the Elderly
A Basic Approach to Mood and Anxiety Disorders in the Elderly November 1 2013 Sarah Colman MD FRCPC Clinical Fellow, Geriatric Psychiatry Mount Sinai Hospital, University of Toronto Disclosure No conflict
More informationChapter 161 Antipsychotics
Chapter 161 Antipsychotics Episode Overview Extrapyramidal syndromes are a common complication of antipsychotic medications. First line treatment is benztropine or diphenhydramine. Lorazepam is used in
More informationLTC Research Influencing Practice
LTC Research Influencing Practice David A. Nace, MD, MPH Division of Geriatric Medicine naceda@upmc.edu PGS Clinical Update April 6, 2017 Conflicts of Interest Dr. Nace does not have any current conflicts
More informationFull details and resource documents available:
Clinical & Regulatory News by Pharmerica Urinary Tract Infection (UTI) Second Most Common Cause of Hospital Readmission within 30 days UTIs are prevalent and account for up to 22% of infections in LTC,
More informationPrescribing for people with dementia. Carol Paton Chief Pharmacist April 2009
Prescribing for people with dementia Carol Paton Chief Pharmacist April 2009 What are the issues? 1. Minimising cognitive side effects from prescribed medicines 2. Prescribing memory enhancing drugs 3.
More informationPsychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan
Psychopharmacology in the Emergency Room Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan Pretest 1. Which of the following conditions is LEAST likely to benefit from emergency
More informationAssessment and management of behavioral. B ehavior al and psychological symptoms of dementia are STATE OF THE ART REVIEW
Assessment and management of behavioral and psychological symptoms of dementia Helen C Kales, 1 2 3 Laura N Gitlin, 4 5 6 Constantine G Lyketsos 7 1 Section of Geriatric Psychiatry, Department of Psychiatry,
More informationAtypical Antipsychotics and the Risk of Diabetes in an Elderly Population in Long-Term Care: A Retrospective Nursing Home Chart Review Study
Atypical Antipsychotics and the Risk of Diabetes in an Elderly Population in Long-Term Care: A Retrospective Nursing Home Chart Review Study Stewart G. Albert, MD, George T. Grossberg, MD, Papan J. Thaipisuttikul,
More information